Each film-coated tablet contains: Metformin Hydrochloride 500 mg.
Pharmacology: Pharmacokinetics: Metformin Hydrochloride is slowly and incompletely absorbed from the gastrointestinal tract; the absolute bioavailability of a single 500-mg dose is reported to be about 50 to 60%, although this is reduced somewhat if taken with food. Following absorption, plasma protein binding is negligible, and it is excreted unchanged in the urine. The plasma elimination half-life is reported to range from about 2 to 6 hours after oral administration.
It is given by mouth in the treatment of type 2 diabetes mellitus.
Given by mouth in the treatment of non insulin-dependent diabetes mellitus in an initial dosage of 500 mg two or three times a day or 850 mg once or twice a day with or after meals, gradually increased if necessary to a maximum of 2 or 3 g daily. Or as prescribed by the physician.
Metformin HCl is contraindicated in patients with renal impairment and liver failure because of an increased risk of hypoglycemia. Renal impairment may also predispose patients to lactic acidosis. Regular renal and hepatic monitoring is essential.
Drug Interactions involve drugs also excreted by the renal tubular pathway (e.g. amiloride, cimetidine, digoxin, morphine, procainamide, quinidine, vancomycin, trimethoprim). Cimetidine may increase Metformin levels by up to 50%.
Metformin Hydrochloride should not be used in insulin dependent diabetes mellitus. Metformin should not be used in patients with heart failure, myocardial infarction, dehydration, acute or chronic alcoholism, or any other condition likely to predispose lactic acidosis.
Use of Metformin HCl is not recommended.
Metformin Hydrochloride causes gastro-intestinal adverse effects such as anorexia, nausea and vomiting; absorption of various substances including vitamin B12 may be impaired. Patients may experience a metallic taste and there may be weight loss. Hypoglycemia is less of a problem with metformin than with the sulfonylureas. Lactic acidosis, sometimes fatal, has occurred but to a lesser extent than with phenformin and it is generally accepted that the lactic acidosis usually occurred in patients whose condition contraindicated the use of metformin, particularly those with renal impairment.
Use of biguanide concomitantly with other drugs that lower blood-glucose concentrations increases the risk of hypoglycemia, while drugs that increase blood glucose may reduce the effect of biguanide therapy.
In general, fewer drug interactions have been reported with biguanides than with sulfonylureas. Alcohol may increase the risk of lactic acidosis as well as of hypoglycemia. Care should be taken if biguanides are given concomitantly with drugs that may impair renal function.
Store at temperatures not exceeding 30°C.
A10BA02 - metformin ; Belongs to the class of biguanides. Used in the treatment of diabetes.
Medglu FC tab 500 mg
100's (P380/box)
Sign Out
